Leukocyte Typing II

VOLUME 2
Human B Lymphocytes
Leukocyte Typing II

Volume 1  Human T Lymphocytes
Volume 2  Human B Lymphocytes
Volume 3  Human Myeloid and Hematopoietic Cells
Preface

The Second International Workshop on Human Leukocyte Differentiation Antigens was held in Boston, September 17–20, 1984. More than 350 people interested in leukocyte differentiation agreed to exchange reagents and participate in this joint venture. All in all, in excess of 400 antibodies directed against surface structures on T lymphocytes, B lymphocytes, and myeloid-hematopoietic stem cells were characterized. Because of the enormous quantity of serologic, biochemical, and functional data, Leukocyte Typing II has been divided into three volumes.

These books represent the written results of workshop participants. They should be helpful to both researchers and clinicians involved in scientific endeavors dealing with these broad fields of immunobiology. To those who delve into the various sections of the volumes, it will become evident that the work speaks for itself.

I am deeply indebted to the section editors, Barton F. Haynes, Volume 1, Human T Lymphocytes, Lee M. Nadler, Volume 2, Human B Lymphocytes, and Irwin D. Bernstein, Volume 3, Human Myeloid and Hematopoietic Cells for their major contributions in planning, executing, and summarizing the workshop, as well as council members John Hansen, Alain Bernard, Laurence Boumsell, Walter Knapp, Andrew McMichael, Cesar Milstein, and Stuart F. Schlossman. I would also like to thank the National Institutes of Health, World Health Organization, and International Union of Immunological Societies for making this meeting possible. Needless to say, I am most grateful to all of my colleagues who contributed to this effort and helped to accelerate the characterization of human immunobiology through their endeavors.

Ellis L. Reinherz, M.D.
Contents

I. Introduction

1. B Cell/Leukemia Panel Workshop: Summary and Comments
   L.M. Nadler 3

II. Serologic Specificity of B Cell/Leukemia Monoclonal Antibodies


4. Screening of Workshop "B" Series Antibodies by Radioimmunobinding to Human Leukocyte Cell Lines and to Cells from Human Lymphoid Tumors  C.M. Steel, P. Elder, K. Guy 69

5. Expression of Lymphocyte Differentiation Antigens in Immunodeficiency Diseases  T.F. Tedder, L.T. Clement, M.J. Crain, M.D. Cooper 79

6. Use of Two Monoclonal Anti-Human B Cell Antibodies in the Study of Early B Cell Differentiation  A. Raghavachar, S.F. Goldmann, B. Kubánek 87

7. Characterization of a Human B Lymphocyte-Specific Antigen Defined by Monoclonal Antibodies HD6 and
HD39  G. Moldenhauer, B. Dörken, R. Schwartz, A. Pezzutto, G.J. Hämmerling 97


10. Human B Cells: Is FMC7 a Marker for Relatively Mature B Cells or Does It Define a Population Equivalent to the LyB5-Negative Mouse B Cells? H. Zola 141


III. Biochemical Analysis of Antigens Defined by the Workshop B Cell/Leukemia Panel


15. Human B Cell Antigens Detected by the Workshop Antibodies: A Comparison of Serological and Immunochemical Patterns K. Horibe, R.W. Knowles 187

16. Further Evidence that the Human Differentiation Antigen p24 Possesses Activity Associated with Protein Kinase T.F. Zipf, G.R. Antoun, G.J. Lauzon, B.M. Longenecker 203


19. Human Neutrophils Synthesize Different Forms of the Common Acute Lymphoblastic Leukemia Antigen  
*R.T. McCormack, J.G. Bradley, T.W. LeBien*  

20. Immunohistochemical Analysis of Monoclonal Anti–B Cell Antibodies  
*D.Y. Mason, H. Ladyman, K.C. Gatter*  

21. Analysis of B and L Workshop Antibodies on Sections of Normal and Neoplastic Lymphoid Tissue and Cell Lines  
*I.C.M. MacLennan, P.D. Nathan, G.D. Johnson, M. Khan, L. Walker, N.R. Ling*  

22. Immunohistological Analysis of Tissue Specificity of the Fifty-two Workshop Anti–B Lymphocyte Monoclonal Antibodies  
*G. Pallesen*  

23. Reactivity of Monoclonal Antibodies of the B and L Series with Follicular Dendritic Cells in Tissue Sections and with Lymphoblastoid Cell Lines  
*G.D. Johnson, I.C.M. MacLennan, N.R. Ling, D.L. Hardie, P.D. Nathan, L. Walker*  

24. The Staining of a Panel of Routine Diagnostic Tissue Biopsies with the Workshop “L” Series Antibodies  
*D.B. Jones, K.M. Britten, D.H. Wright*  

25. Immunohistochemical Reactivity of Anti–B Cell Monoclonal Antibodies in Thymus, Lymph Node, and Normal Skin  
*E. Berti, C. Parravicini, G. Cattoretti, D. Delia, F. de Braud, M. Cusini*  

*N. Kraft, P.S. Giddy, W.W. Hancock, R.C. Atkins*  

27. Quantitative Phenotypes of B Chronic Lymphocytic Leukemia B Cells Established with Monoclonal Antibodies from the B Cell Protocol  
*P. Poncelet, T. Lavabre-Bertrand, P. Carayon*
Contents

28. Analysis of Workshop "L" Series Antibodies: Radioimmunobinding and Biochemical Studies
   C.M. Steel, B.B. Cohen, P. Elder, M. Moxley, K. Guy 345

29. Subclassification of Leukemia Using Monoclonal Antibodies  G.R. Pilkington, G.T.H. Lee,
   P.M. Michael, O.M. Garson, N. Kraft, R.C. Atkins, D.G. Jose 353

30. Immunological Classification of "Unclassifiable" Acute Leukemia  F. Herrmann, B. Dörken, A. Gatzke,
   W.D. Ludwig 367


32. Heterogeneity of B-CLL Cells Defined by Monoclonal Antibodies  N. Genetet, D. Bourel, B. Grosbois,
   G. Merdrignac, M. Marty, R. Fauchet, F. Lancelin, R. Leblay, B. Genetet 385

33. HD37 Monoclonal Antibody: A Useful Reagent for Further Characterization of "Non-T, Non-B" Lymphoid Malignancies  A. Pezzutto, B. Dörken, A. Feller,
   G. Moldenhauer, R. Schwartz, P. Wernet, E. Thiel, W. Hunstein 391


VI. Functional Significance of Human B Cell/Leukemia Antigens

35. Human B Cell Populations Defined by the B1 and B2 Antigens  K.C. Anderson, A.W. Boyd, D.C. Fisher,
   J.F. Daley, S.F. Schlossman, L.M. Nadler 413

36. Phenotypic Changes Occurring during in vitro Activation of Human Splenic B Lymphocytes  A.W. Boyd,

A.S. Freedman, A.W. Boyd, D.C. Fisher, S.F. Schlossman, L.M. Nadler  

43. Activation of Human B Cells with Monoclonal Antibody to the Bp32 Cell Surface Polypeptide  

E.A. Clark, G. Shu, J.A. Ledbetter  

455

39. B Lymphocyte Surface Antigens Involved in the Regulation of Immunoglobulin Secretion  

J. Golay, F. Rawle, P. Beverley  

463

40. Inhibition of Immunoglobulin Secretion, But Not Immunoglobulin Synthesis, by a Monoclonal Antibody  

S. Pittaluga, J. Cossman, J.B. Trepel, L.M. Neckers  

473

41. Monoclonal Antibody AB1 Identifies a Human B Cell Activation Antigen and Inhibits Growth Factor-Dependent Human B Cell Proliferation  

L.K.L. Jung, S.M. Fu, J. Morgan, A.L. Maizel  

483

42. Detection and Functional Studies of IL-2 Receptors on Activated Human B Cells  

L.K.L. Jung, T. Hara, S.M. Fu  

491

43. The C3d Receptor Identified by the HB-5 Monoclonal Antibody: Expression and Role as a Receptor for Epstein–Barr Virus  


499

44. The B Cell-Restricted Glycoprotein (B2) Is the Receptor for Epstein–Barr Virus  


509

45. Monoclonal Antibody-Defined Cell Surface Molecules Regulate Lymphocyte Activation  

D.R. Howard, A.C. Eaves, F. Takei  

519

46. TPA-Induced Modulation of B Cell Differentiation Antigens Defined by Monoclonal Antibodies (HD6, HD28, HD37, HD39)  

R. Schwartz, G. Moldenhauer, B. Dörken, A. Pezzutto, F. Momburg, V. Schirrmacher  

527

47. Functional Studies of p24: Platelet Aggregation Inhibition by Fab Monomers of BA-2  


541

Index  

551
Contributors

Kenneth C. Anderson  Division of Tumor Immunology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, U.S.A.

Ignacio Anegón  Servicio de Inmunología, Hospital Clínica i Provincial, 08036 Barcelona, Spain

Gamil R. Antoun  Department of Pediatrics and the Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada T2N 4N1

Robert C. Atkins  Nephrology Department, Prince Henry’s Hospital, Melbourne, Australia

Emilio Berti  First Department of Dermatology, University of Milan, Milan, Italy

Peter Beverley  ICRF Human Tumor Immunology Group; School of Medicine, University College London, London WC1E 6JJ, U.K.

Luis Borche  Servicio de Inmunología, Hospital Clínica i Provincial, 08036 Barcelona, Spain

D. Bourel  Groupe Universitaire de Recherche en Immunologie Fondamentale et Appliquée, Service de Médecine Interne, Département d’Hematologie, C.H.U., Rennes, France

Andrew W. Boyd  Division of Tumor Immunology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115 U.S.A.

J. Garrett Bradley  Department of Laboratory Medicine/Pathology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, U.S.A.

K.M. Britten  University Department of Pathology, General Hospital Southampton SO9 4XY, U.K.

Jo Ellen Brown  University of Minnesota, Minneapolis, Minnesota 55455, U.S.A.

Pierre Carayon  Immunotoxin Project, Research Center Clin-Midy, Sanofi Group, Montpellier, France
Giorgio Cattoretti  National Cancer Institute of Milan, Milan, Italy
Edward A. Clark  Department of Microbiology and Immunology, University of Washington, Seattle, Washington 98195, U.S.A.
Loran T. Clement  Cellular Immunobiology Unit, Tumor Institute, University of Alabama in Birmingham, Birmingham, Alabama 35294, U.S.A.
B.B. Cohen  Medical Research Council, Clinical and Population Cytogenetics Unit, Western General Hospital, Edinburgh, U.K.
Max D. Cooper  Cellular Immunobiology Unit, Tumor Institute, University of Alabama in Birmingham, Birmingham, Alabama 35294, U.S.A.
Jeffrey Cossman  Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205, U.S.A.
Marilyn J. Crain  Cellular Immunobiology Unit, Tumor Institute, University of Alabama in Birmingham, Birmingham, Alabama 35294, U.S.A.
Marco Cusini  First Department of Dermatology, University of Milan, Milan, Italy
Cristina Cuturi  Servicio de Inmunología, Hospital Clínica i Provincial, 08036 Barcelona, Spain
John F. Daley  Division of Tumor Immunology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, U.S.A.
Filippo de Braud  National Cancer Institute of Milan, Milan, Italy
Domenico Delia  National Cancer Institute of Milan, Milan, Italy
Bernd Dörken  Medizinische Universitäts-Poliklinik, D-6900 Heidelberg, F.R.G.
Allen C. Eaves  Terry Fox Laboratory, B.C. Cancer Research Centre, Vancouver, British Columbia, Canada
David Einfeld  Immunobiology Group, Genetic Systems Corporation, Seattle, Washington 98121, U.S.A.
Patricia Elder  Medical Research Council Clinical and Population Cytogenetics Unit, Western General Hospital, Edinburgh, U.K.
Ilse Marie Fastrup  The University Department of Medicine and Hematology, Aarhus Amtssygehus, Denmark DK-8000
R.Fauchet  Groupe Universitaire de Recherche en Immunologie Fondamentale et Appliquée, Service de Médecine Interne, Département d’Hématologie, C.H.U., Rennes, France
Douglas T. Fearon  Department of Medicine, Harvard Medical School, Department of Rheumatology & Immunology, Brigham and Women’s Hospital, Boston, Massachusetts 02115, U.S.A.
A. Feller  Pathologisches Institute der Universität Kiel, Kiel, F.R.G.
David C. Fisher  Division of Tumor Immunology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, U.S.A.
Arnold S. Freedman  Division of Tumor Immunology, Dana-Farber Cancer institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, U.S.A.

Shu Man Fu  Cancer Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, U.S.A.

Teresa Gallart  Servicio de Inmunología, Hospital Clínica i Provincial, 08036 Barcelona, Spain

O. Margaret Garson  Immunogenetics Research Unit, Cancer Institute, Melbourne, Australia 3000

K.C. Gatter  Department of Haematology, John Radcliffe Hospital, Oxford OX3 9DU, U.K.


B. Genetet  Groupe Universitaire de Recherche en Immunologie Fondamentale et Appliquée, Service de Medecine Interne, Departement d’Hematologie, C.H.U., Rennes, France

N. Genetet  Groupe Universitaire de Recherche en Immunologie Fondamentale et Appliquée, Service de Médecine Interne, Département d’Hématologie, C.H.U., Rennes, France

Peter S. Giddy  Nephrology Department, Prince Henry’s Hospital, Melbourne, Australia

Josée Golay  ICRF Human Tumor Immunology Group, School of Medicine, University College London, London WC1E 6JJ, U.K.

Shraga F. Goldmann  Red Cross Blood Bank Ulm, Department of Transfusion Medicine, University of Ulm, D-7900 Ulm, F.R.G.

Walter Goldschmids  Pediatric Branch, Clinical Oncology Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205, U.S.A.

B. Grosbois  Groupe Universitaire de Recherche en Immunologie Fondamentale et Appliquée, Service de Médecine Interne, Département d’Hématologie, C.H.U., Rennes, France

Keith Guy  Medical Research Council Clinical and Population Cytogenetics Unit, Western General Hospital, Edinburgh, U.K.

Günter J. Hämmerling  Institut für Immunologie und Genetik, Deutsches Krebsforschungszentrum, D-6900 Heidelberg, F.R.G.

Kathleen R. Hagert  University of Minnesota, Minneapolis, Minnesota 55455, U.S.A.

Wayne W. Hancock  Nephrology Department, Prince Henry’s Hospital, Melbourne, Australia

Toshiro Hara  Cancer Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, U.S.A.

D.L. Hardie  Department of Immunology, The Medical School, University of Birmingham, Birmingham B15 2TJ, U.K.

Contributors

R.D. Hockett, Jr.  University of Minnesota, Minneapolis, Minnesota 55455, U.S.A.

Peter Hokland  The University Department of Medicine and Hematology, Aarhus Amtssygehus, Denmark DK-8000

Keizo Horibe  Human Immunogenetics Laboratory, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, U.S.A.

J.C. Horowitz  Division of Tumor Immunology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, U.S.A.

Donald R. Howard  Terry Fox Laboratory, B.C. Cancer Research Centre, Vancouver, British Columbia, Canada

W. Hunstein  Medizinische Universitäts-Poliklinik, D-6900 Heidelberg, F.R.G.

Yoshifumi Ishii  Department of Pathology, Sapporo Medical College, S1 W17 Sapporo 060, Japan

G.D. Johnson  Department of Immunology, University of Birmingham, Medical School, Birmingham B15 2TJ, U.K.

D.B. Jones  University Department of Pathology, General Hospital, Southampton SO9 4XY, U.K.

David G. Jose  Immunogenetics Research Unit, Cancer Institute, Melbourne, Australia 3000

Lawrence K.L. Jung  Cancer Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, U.S.A.

John H. Kersey  University of Minnesota, Minneapolis, Minnesota 55455, U.S.A.

M. Khan  Department of Immunology, University of Birmingham, Medical School, Birmingham B15 2TJ, United Kingdom

S. Kiesel  Medizinische Universitäts-Poliklinik, D-6900 Heidelberg, F.R.G.

Kokichi Kikuchi  Department of Pathology, Sapporo Medical College, S1 W17 Sapporo 060, Japan

James Kiwanuka  Pediatric Branch, Clinical Oncology Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205, U.S.A.

Jeroen Knops  Institute für Immunologie und Genetik, Deutsches Krebsforschungszentrum, D-6900 Heidelberg, F.R.G.

Robert W. Knowles  Human Immunogenetics Laboratory, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, U.S.A.

Yasuo Kokai  Department of Pathology, Sapporo Medical College, S1 W17 Sapporo 060, Japan

Norbert Kraft  Nephrology Department, Prince Henry’s Hospital, Melbourne, Australia

Bernhard Kubanek  Red Cross Blood Bank Ulm, Department of Transfusion Medicine, University of Ulm, D-7900 Ulm, F.R.G.
H. Ladyman  Department of Haematology, John Radcliffe Hospital, Oxford OX3 9DU, U.K.

F. Lancelin  Groupe Universitaire de Recherche en Immunologie Fondamentale et Appliquée, Service de Médecine Interne, Département d'Hématologie, C.H.U., Rennes, France

Gilles J. Lauzon  Department of Pediatrics and the Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada T2N 4N1

Thierry Lavabre-Bertrand  Service des Maladies du Sang, C.H.U., Montpellier, France

A.M. Lebaq-Verheyden  Unité de Recherches sur les Maladies du Sang, Université Catholique de Louvain, Brussels, Belgium

Tucker W. LeBien  Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota 55455, U.S.A.

R. Leblay  Groupe Universitaire de Recherche en Immunologie Fondamentale et Appliquée, Service de Médecine Interne, Département d'Hématologie, C.H.U. Rennes, France

Jeffrey A. Ledbetter  Immunobiology Group, Genetic Systems Corporation, Seattle, Washington 98121, U.S.A.

Grace T.H. Lee  Immunogenetics Research Unit, Cancer Institute, Melbourne, Australia 3000

N.R. Ling  Department of Immunology, University of Birmingham, Medical School, Birmingham B15 2TJ, U.K.

B. Michael Longenecker  Department of Immunology, University of Alberta, Edmonton, Alberta, Canada T6G 2H7


I.C.M. MacLennan  Department of Immunology, University of Birmingham, Medical School, Birmingham B15 2TJ, U.K.

Ian T. Magrath  Pediatric Branch, Clinical Oncology Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205, U.S.A.

Abby L. Maizel  Department of Pathology, Section of Pathobiology, The University of Texas Cancer Center, Houston, Texas 77030, U.S.A.

Gerald E. Marti  Hematology Service, Clinical Pathology Department, National Institutes of Health, Bethesda, Maryland 20205, U.S.A.

M. Marty  Groupe Universitaire de Recherche en Immunologie Fondamentale et Appliquée, Service de Médecine Interne, Département d'Hématologie, C.H.U., Rennes, France

D.Y. Mason  Department of Haematology, John Radcliffe Hospital, Oxford OX3 9DU, U.K.

Robert T. McCormack  Department of Laboratory Medicine/Pathology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, U.S.A.
Contributors

G. Merdrignac  Groupe Universitaire de Recherche en Immunologie Fondamentale et Appliquée, Service de Médecine Interne, Département d’Hématologie, C.H.U., Rennes, France

Karin Meyer  The University Department of Medicine and Hematology, Aarhus Amtssygehus, Denmark DK-8000

Patricia M. Michael  Immunogenetics Research Unit, Cancer Institute, Melbourne, Australia 3000

Jordi Milà  Servicio de Inmunología, Hospital Clínico i Provincial, 08036 Barcelona, Spain

Gerhard Moldenhauer  Institut für Immunologie und Genetik, Deutsches Krebsforschungszentrum, D-6900 Heidelberg, F.R.G.

Frank Momburg  Institut für Immunologie und Genetik, Deutsches Krebsforschungszentrum, D-6900 Heidelberg, F.R.G.

John Morgan  Department of Pathology, Section of Pathobiology, The University of Texas Cancer Center, Houston, Texas 77030, U.S.A.

Marion Moxley  Medical Research Council, Clinical and Population Cytogenetics Unit, Western General Hospital, Edinburgh, U.K.

Lee M. Nadler  Division of Tumor Immunology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, U.S.A.

P.D. Nathan  Department of Immunology, University of Birmingham, Medical School, Birmingham B15 2TJ, U.K.

Leonard M. Neckers  Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205, U.S.A.

G. Pallesen  University Institute of Pathology, Kommunehospitalet, DK-8000 Aarhus C, Denmark

Edward Park  Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, U.S.A.

Carlo Parravicini  Fifth Department of Pathology, University of Milan, Milan, Italy

Antonio Pezzutto  Medizinische Universitäts-Poliklinik, D-6900 Heidelberg, F.R.G.

Glenn R. Pilkington  Immunogenetics Research Unit, Cancer Institute, Melbourne, Australia 3000

Samuel J. Pirruccello  Department of Laboratory Medicine/Pathology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, U.S.A.

Stefania Pittaluga  Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205, U.S.A.

Jeffrey L. Platt  Department of Laboratory Medicine/Pathology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, U.S.A.

Philippe Poncelet  Immunotoxin Project, Research Center Clin-Midy, Sanofi Group, Montpellier, France
Contributors

Anand Raghavachar  Red Cross Blood Bank Ulm, Department of Transfusion Medicine, University of Ulm, D-7900 Ulm, F.R.G.

A.M. Ravoet  Unité de Recherches sur les Maladies du Sang, Université Catholique de Louvain, Brussels, Belgium

Frances Rawle  ICRF Human Tumor Immunology Group, School of Medicine, University College London, London WC1E 6JJ, U.K.

H. Riehm  Abt. Pädiatrie VI, Medizinische Hochschule Hannover, Hannover, F.R.G.

John T. Sandlund  Pediatric Branch, Clinical Oncology Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205, U.S.A.

Volker Schirrmacher  Institute of Immunology and Genetics, German Cancer Research Center, D-6900 Heidelberg, F.R.G.

Stuart F. Schlossman  Division of Tumor Immunology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, U.S.A.

Reinhard Schwartz  Institut für Immunologie und Genetik, Deutsches Krebsforschungszentrum, D-6900 Heidelberg, F.R.G.

Geraldine Shu  Immunobiology Group, Genetic Systems Corporation, Seattle, Washington 98121, U.S.A.

Bruce Slaughenhoupt  Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, U.S.A.

C.M. Steel  Medical Research Council Clinical and Population Cytogenetics Unit, Western General Hospital, Edinburgh, U.K.

Tsuyoshi Takami  Department of Pathology, Sapporo Medical College, S1 W17 Sapporo 060, Japan

Fumio Takei  Terry Fox Laboratory, B.C. Cancer Research Centre, Vancouver, British Columbia, Canada

Takashi Takei  Department of Pathology, Sapporo Medical College, S1 W17 Sapporo 060, Japan

Thomas F. Tedder  Cellular Immunobiology Unit, Tumor Institute, University of Alabama in Birmingham, Birmingham, Alabama 35294, U.S.A.

E. Thiel  Institute für Haematologie, München, F.R.G.

David A. Thorley-Lawson  Departments of Pathology and Medicine, Tufts University School of Medicine, Boston, Massachusetts 02115, U.S.A.

Jane B. Trepel  Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205, U.S.A.

Ramón Vilella  Servicio de Inmunología, Hospital Clínica i Provincial, 08036 Barcelona, Spain

Jordi Vives  Servicio de Inmunología, Hospital Clínica i Provincial, 08036 Barcelona, Spain

L. Walker  Department of Immunology, University of Birmingham, Medical School, Birmingham B15 2TJ, U.K.
Janis J. Weis  Department of Medicine, Harvard Medical School, Department of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, Massachusetts 02115, U.S.A.

P. Wernet  Medizinische Universitäts-Klinik, Tübingen, F.R.G.

James G. White  University of Minnesota, Minneapolis, Minnesota 55455, U.S.A.

D.H. Wright  University Department of Pathology, General Hospital, Southampton SO9 4XY, U.K.

Hiroo Yuasa  Department of Pathology, Sapporo Medical College, S1 W17 Sapporo 060, Japan

Theodore F. Zipf  Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada T2N 4N1

Heddy Zola  Flinders Medical Centre and Flinders University of South Australia, Bedford Park, South Australia 5042